• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1276437 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
, V3 a. ^9 P$ x! m4 HNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
. y3 H/ Z) {9 j+ Author Affiliations, k3 H# p& y. M9 p6 Z& `

$ A2 T% O, \, i6 E9 N1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
! N& j& n" W. M+ s' Z/ w! p2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
& R$ r0 D5 U& N3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan - {6 {1 B# ?; ]6 L
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 7 R5 e) U5 F+ k8 }
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
, ~- X" J: E# h3 s; f6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan # y/ ~6 ^% d, L( T/ x
7Kinki University School of Medicine, Osaka 589-8511, Japan
% n& D1 i2 g  l, _( Q8 Q0 S/ \" t# Y8Izumi Municipal Hospital, Osaka 594-0071, Japan
) b# g- k5 q6 \( b. a9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
( ~* `/ e; h1 QCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp . Z' K- m7 o+ L
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
: l9 g, ^) L1 h; t4 M
- N( v1 s5 N7 v+ d+ k9 z; R
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
2 t8 u$ w% }: b6 w1 P/ ^6 Z8 l) x1 q
- {2 X/ w2 f; {8 ?3 aAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato & C8 I: s& L6 D. D9 ]

- W0 d7 X8 U- Z6 jAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
7 J5 A% l" r3 D$ d
9 s7 ], Z' d" C% p5 [Published online on: Thursday, December 1, 2011
7 Q# a1 w' m+ X3 a  h9 o2 Y9 B( M! ^. W+ w0 b
Doi: 10.3892/ol.2011.507
- N2 o) X. B9 [/ _
* y- t' X6 v  p9 h# E% jPages: 405-410
4 {/ ~, r5 D5 S- z' X, F( f
" }' @. o1 S# `' {9 [Abstract:
4 s9 ]$ D. _; n; e( nS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.! N* q; m: k  W/ H) x  }
. |# d0 v2 K! I3 z  d0 Q
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population5 o8 ]* Y! ]. s5 n7 T3 B
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 . @1 Q, O! [, Q4 U& [0 {6 _' v: @# c
+ Author Affiliations5 R! Z* f& C& ]0 M
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu ) e! t8 l- D: X  K1 d  _( R" ^- |
2Department of Thoracic Surgery, Kyoto University, Kyoto
. N# w! d2 B, B) h$ ~7 u- M; n; i$ H3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
$ I) S3 o* C4 T# b4 O7 z' Q&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
# `' p. I1 N5 iReceived September 3, 2010.
9 c( I' A1 x& o, q8 x# w: uRevision received November 11, 2010. % P5 e% H/ B) b3 n! T
Accepted November 17, 2010. 7 h! J7 {. N" G) J. G7 o: V
Abstract
6 J. t; N% ?4 C6 C3 m6 |Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
. ]9 h1 N: J: _0 h' @Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. & R% r8 \+ @: a* l
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
+ g  I8 `7 t7 s% LConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
1 R, T% M5 ?1 R8 T( g3 P
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
. N% Q1 h: d" H( M# d+ k; f今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
+ u; S, M6 U/ ~7 \& P
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy: l9 u4 m8 F: H# P; i( Z  B
http://clinicaltrials.gov/ct2/show/NCT01523587% Q6 Z, u7 d% q6 j/ \
2 J, B: ~4 p- k. E, C: z* }" z! B
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
" \! t  C! f/ @4 o. zhttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 0 i; _' m/ G4 w+ e5 A% g  J* z5 Z3 K
. `. p, Q- }% H2 }8 O/ p* o$ ], d
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。! q- M& p! g3 {9 K5 U3 `* d( D
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 , U7 b6 u6 T9 V
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。1 c& s2 v& @, [% R8 ^% i: f1 T
至今为止,未出 ...

9 H+ c# M. t, y/ D没有副作用是第一追求,效果显著是第二追求。4 Y( ^" V+ P5 q2 ~" J) D7 A
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表